The bill enacts the "Right to Try for Individualized Treatments Act" in Kansas, allowing eligible patients with life-threatening or severely debilitating illnesses to access individualized investigational treatments. To qualify, patients must have a recommendation from their physician, have considered all FDA-approved treatment options, and provide written informed consent. The bill defines key terms such as "biospecimen," "eligible patient," and "individualized investigational treatment," which includes treatments tailored to a patient's genetic profile. It also outlines the responsibilities of manufacturers and eligible facilities in providing these treatments, including the option for patients to cover associated costs.

Additionally, the bill includes provisions to protect healthcare providers from disciplinary actions based solely on their recommendations for individualized treatments and ensures that patients' estates are not liable for debts incurred from treatments if the patient dies. It clarifies that the act does not expand insurance coverage requirements and does not create a private cause of action against manufacturers or providers for harm resulting from the treatments, provided they comply with the act's terms. The act will take effect upon publication in the statute book.